226 related articles for article (PubMed ID: 37407650)
1. Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Xiao Y; Chen Y; Huang Y; Xiao Y
Sci Rep; 2023 Jul; 13(1):10892. PubMed ID: 37407650
[TBL] [Abstract][Full Text] [Related]
2. Polypharmacy in Osteoporosis Treatment.
McConnell M; Shieh A
Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
[TBL] [Abstract][Full Text] [Related]
3. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
4. Association Between Antiosteoporotic Drugs and Risk of Acute Kidney Injury: A Cross-Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database.
Mitsuboshi S; Kaseda R; Narita I
J Clin Pharmacol; 2022 Nov; 62(11):1419-1425. PubMed ID: 35665942
[TBL] [Abstract][Full Text] [Related]
5. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
Peng J; Wang H; Liu Z; Xu ZL; Wang MX; Chen QM; Wu ML; Ren XL; Liang QH; Liu FP; Ban B
Front Pharmacol; 2022; 13():1017391. PubMed ID: 36339548
[No Abstract] [Full Text] [Related]
6. Efficacy, effectiveness and side effects of medications used to prevent fractures.
Reid IR
J Intern Med; 2015 Jun; 277(6):690-706. PubMed ID: 25495429
[TBL] [Abstract][Full Text] [Related]
7. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Pedersen AB; Risbo N; Kafatos G; Neasham D; O'Kelly J; Ehrenstein V
Arch Osteoporos; 2023 Jan; 18(1):19. PubMed ID: 36629929
[TBL] [Abstract][Full Text] [Related]
8. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
9. Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease.
Lai KH; Chiang CY; Yang RS; Yang KC; Wu CC
Acta Clin Belg; 2019 Oct; 74(5):370-374. PubMed ID: 30336748
[No Abstract] [Full Text] [Related]
10. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
[TBL] [Abstract][Full Text] [Related]
12. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
13. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
14. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Migliorini F; Maffulli N; Colarossi G; Eschweiler J; Tingart M; Betsch M
J Orthop Surg Res; 2021 Aug; 16(1):533. PubMed ID: 34452621
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
16. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile.
McConeghy KW; Soriano MM; Danziger LH
Pharmacotherapy; 2016 Oct; 36(10):1095-1101. PubMed ID: 27582058
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
18. Which Drug Next? Sequential Therapy for Osteoporosis.
Lukert BP
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31922566
[TBL] [Abstract][Full Text] [Related]
19. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
20. Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration.
Mammo Z; Guo M; Maberley D; Matsubara J; Etminan M
Am J Ophthalmol; 2016 Aug; 168():62-67. PubMed ID: 27163238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
